Search Results for: formulation development amorphous dispersion formu
Articles
Catalent Boston Adds to Oral Spray Drying Capacity & Capabilities to Support Late-Stage Clinical Trials & Commercialization October 28, 2024
Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies, and flexible manufacturing, has completed a series of...Hovione & Zerion Pharma Create Joint Venture to Further Expand Use of Dispersome Technology October 3, 2024
Hovione Farmaciência, S.A. and Zerion Pharma A/S recently announced they have expanded their partnership to accelerate the development of the...EXECUTIVE INTERVIEW - Lonza: Navigating Today’s Challenges in Drug Solubility & Bioavailability June 3, 2024
Adi Kaushal, Director and Technology Head, Bioavailability Enhancement at Lonza, discusses solubility and bioavailability challenges and Lonza’s approach.
Data From First Human Study Demonstrate Excellent Performance of Zerion Pharma’s Dispersome Technology May 13, 2024
Zerion Pharma A/S recently announced positive results from the first human clinical study of a Dispersome formulation of the drug...Elizabeth Hickman to Succeed Tim Scott as AustinPx CEO March 5, 2024
AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol Technology, and a contract development and manufacturing organization (CDMO), recently announced Elizabeth Hickman, Chief Business Officer, will succeed….
SPECIAL FEATURE - Improving Bioavailability & Solubility: The Never-Ending Quest February 29, 2024
Contributor Cindy H. Dubin speaks with several companies to review their innovative technologies in this annual report on bioavailability and solubility.
PBPK MODELING - Critical Parameters for Simulating Oral Absorption Using PBPK Models February 29, 2024
Deanna Mudie, PhD, says with an increasing number of drugs posing absorption challenges, the ability to predict how a new molecule will behave in vivo is important, and being able to predict and mitigate absorption problems before they arise should help the project progress with fewer delays.
AustinPx Partners With Microsize on KinetiSol Technology, Partnership Strengthens Commercialization Options for AustinPx’s Clients January 31, 2024
AustinPx and Microsize recently announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol Technology platform. The collaboration will enable….
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide January 8, 2024
Nanoform Finland Plc recently announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the...Ascendia Named to 2023 Inc. 5000 List of America’s Fastest-Growing Private Companies for the Fourth Consecutive Year August 25, 2023
Ascendia Pharmaceuticals®, a leading specialty pharmaceutical contract development and manufacturing organization (CDMO) in North America, proudly announces it has been...EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems May 1, 2023
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
BIOAVAILABILITY ENHANCEMENT - Solving Low Solubility Challenges to Optimize Drug Delivery Platforms April 3, 2023
David K. Lyon, PhD, discusses how low aqueous solubility NCEs have come to define the innovative pharmaceutical pipelines and how advanced technologies are often required to overcome this issue.
Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs March 29, 2023
Catalent recently announced the launch of the ProteoSuite Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into….
SPECIAL FEATURE - Solubility & Bioavailability: Difficult Beasts to Tame March 1, 2023
Contributor Cindy H. Dubin highlights the services many of these outsourced providers offer to enhance solubility and bioavailability and get their clients’ projects to market faster and cost effectively – while maintaining critical quality attributes.
Hovione & GEA announce a Strategic Collaboration to Advance Continuous Tableting December 14, 2022
Hovione & GEA recently announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years….
SOLUBILITY ENHANCEMENT - How Microparticles are Opening Doors to New Solutions for Oral Drug Delivery August 31, 2022
Jessica Mueller-Albers, PhD, Yiming Ma, PhD, Alexander Bernhardt, PhD, and Michael Damm review the use of microparticles for solubility enhancement of oral small molecules and how this approach can address the challenges in pharmaceutical formulations.
Lubrizol Life Science Health Launches Innovative Apisolex(TM) Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products May 3, 2022
Lubrizol Life Science (LLS) Health, a global leader in accelerating success and innovation in pharmaceutical development, has launched Apisolex, a novel solubility-enhancing excipient for use in….
SPECIAL FEATURE - Excipients: Exciting Expansion & Innovation April 4, 2022
Contributor Cindy H. Dubin speaks with several companies and presents a unique look at how excipients are being used to support current and future innovative active pharmaceutical ingredients.
SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
Hovione & Zerion Pharma Announce Strategic Partnership February 22, 2022
Hovione recently announced a strategic partnership with Zerion Pharma to market and commercialize Dispersome, Zerion´s proprietary solubility enhancement….
Presentation: Strategies for Amorphous Solid Dispersion Product Development
In this presentation, Dr. Schlesinger demonstrates how to leverage a combination of measured and calculated molecular properties, bio-performance modeling, and a strategic understanding of the product TPP to identify a technology to enable exposure and an appropriate drug product design…..
